BioCardia has been granted a patent for a method of treating various diseases and disorders using mesenchymal stem cells (MSCs) that express the neurokinin-1 receptor (NK1R+ MSCs). The method involves isolating these cells from a patient’s bone marrow and administering them to the patient to treat conditions such as cardiovascular disease, pain, rheumatoid arthritis, diabetes, stroke, asthma, pulmonary fibrosis, and aging. GlobalData’s report on BioCardia gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioCardia, Shapeable guide catheters was a key innovation area identified from patents. BioCardia's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Use of neurokinin 1 receptor to isolate and treat diseases
A recently granted patent (Publication Number: US11642377B2) describes a method for treating various diseases and disorders using mesenchymal stem cells (MSCs) that express the neurokinin-1 receptor (NK1R+ MSCs). The method involves isolating these NK1R+ MSCs from the bone marrow of a human subject using an antibody to NK1R and administering them to a patient in a therapeutically effective amount.
The diseases and disorders that can be treated using this method include cardiovascular disease, pain, rheumatoid arthritis, diabetes, stroke, asthma, pulmonary fibrosis, and aging. The NK1R+ MSCs can be isolated from different types of donors, including autologous, syngeneic, allogeneic, or xenogeneic.
After administration, the NK1R+ MSCs have the potential to differentiate into various lineages, such as myocardial, vascular, or endothelial lineages. The differentiation into myocardial lineage can be identified by markers like GATA-4, Nkx2.5, or sarcomeric actin. Differentiation into vascular lineage can be identified by markers like smooth muscle actin or SMA22, while differentiation into endothelial lineage can be identified by markers like CD31 or vimentin.
In addition to the NK1R+ MSCs, one or more agents can be administered to the patient, including cytokines, chemotactic factors, growth factors, or differentiation factors. The concentration of NK1R+ MSCs administered to the patient can vary over a period of time.
For cardiovascular disease, the NK1R+ MSCs can be engrafted in the heart in vivo in infarct and border zones. The NK1R+ MSCs can also be conditioned with media derived from heart stromal cells before administration. They can be cultured and expanded ex vivo prior to administration, either in a hollow fiber bioreactor or in a medium containing substance P.
The patent also includes a second method for treating diseases and disorders using NK1R+ MSCs. This method involves isolating the MSCs from the bone marrow, culturing and expanding them ex vivo, and then administering them to the patient in a therapeutically effective amount. The diseases and disorders that can be treated using this method are the same as mentioned earlier.
Overall, this patent provides a method for treating various diseases and disorders using NK1R+ MSCs, offering potential therapeutic options for conditions such as cardiovascular disease, pain, rheumatoid arthritis, and more.
To know more about GlobalData’s detailed insights on BioCardia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
